Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which glaucoma surgery is safer? new study analyzes vision loss risks

NCT ID NCT07237555

Knowledge-focused Sponsor: Gangnam Severance Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Sep 11, 2026 · Updated 3 times

Summary

This study reviewed medical records of 523 people with severe glaucoma who had one of two surgeries: trabeculectomy or Ahmed glaucoma valve implantation. Researchers wanted to see which factors, like early eye pressure control, were linked to central vision loss after surgery. The goal is to help doctors choose safer surgical approaches for patients with advanced glaucoma.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

523 people

The number who actually took part.

Started

Nov 2024

Finished

Nov 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with severe-stage glaucoma who underwent trabeculectomy or Ahmed glaucoma valve implantation at Gangnam Severance Hospital, Yonsei University College of Medicine, between January 2005 and October 2023, with at least 1-year follow-up data available.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 1\. Patients who underwent trabeculectomy or Ahmed glaucoma valve implantation at Yonsei Medical Center between January 2005 and October 2024. 2\. Glaucoma patients who underwent static quantitative perimetry (visual field test) before and after surgery. 3\. Patients with a preoperative Mean Deviation (MD) of ≤ -20 dB. Exclusion Criteria: * 1\. Patients who were unable to undergo visual field testing due to poor preoperative visual acuity. 2\. Patients with central visual field defects caused by retinal or neurological diseases other than glaucoma. 3\. Patients with false-positive or false-negative responses ≥33% on visual field testing.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Severe-stage glaucoma (mean deviation ≤ -20 DB) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Severe-stage glaucoma (mean deviation ≤ -20 DB)

Contacts and locations

Locations

  • Gangnam Severacne Hospital

    Seoul, Seoul, South Korea